SEC Form 3 filed by new insider Turner Ian Lawrence
$RADX
Biotechnology: Pharmaceutical Preparations
Health Care
| FORM 3 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
| |||||||||||||||
1. Name and Address of Reporting Person*
(Street)
(Country) | 2. Date of Event Requiring Statement
(Month/Day/Year) 03/18/2026 | 3. Issuer Name and Ticker or Trading Symbol
Radiopharm Theranostics Ltd [ RADX ] | |||||||||||||||
| 3a. Foreign Trading Symbol
| 5. If Amendment, Date of Original Filed
(Month/Day/Year) | ||||||||||||||||
| 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
| 6. Individual or Joint/Group Filing (Check Applicable Line)
| ||||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Ordinary Shares | 6,985,292 | D | |
| Ordinary Shares | 3,000,000 | I | Held through the Turner Discretionary Trust, of which Mr. Turner is the sole beneficiary |
| Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Option (right to buy) | (1) | 07/01/2030 | Ordinary Shares | 6,814,000 | $0.025 | D | |
| Option (right to buy) | 09/30/2025 | 09/30/2029 | Ordinary Shares | 2,666,667 | $0.06 | D | |
| Option (right to buy) | (2) | 09/30/2029 | Ordinary Shares | 5,333,333 | $0.06 | D | |
| Option (right to buy) | 07/01/2025 | 06/30/2029 | Ordinary Shares | 1,346,801 | $0.041 | D | |
| Option (right to buy) | (3) | 06/30/2029 | Ordinary Shares | 2,693,603 | $0.041 | D | |
| Option (right to buy) | 09/12/2024 | 08/24/2026 | Ordinary Shares | 1,125,000 | $0.06 | D | |
| Option (right to buy) | 07/01/2024 | 07/01/2028 | Ordinary Shares | 483,622 | $0.112 | D | |
| Option (right to buy) | 07/01/2025 | 07/01/2028 | Ordinary Shares | 483,622 | $0.112 | D | |
| Option (right to buy) | (4) | 07/01/2028 | Ordinary Shares | 483,768 | $0.112 | D | |
| Option (right to buy) | 07/01/2023 | 07/30/2027 | Ordinary Shares | 550,448 | $0.17 | D | |
| Option (right to buy) | 07/01/2024 | 07/30/2027 | Ordinary Shares | 550,448 | $0.17 | D | |
| Option (right to buy) | 07/01/2025 | 07/30/2027 | Ordinary Shares | 550,614 | $0.17 | D | |
| Option (right to buy) | 09/12/2024 | 08/24/2026 | Ordinary Shares | 750,000 | $0.06 | I | Held through Mr. Turner's superannuation fund |
| Option (right to buy) | 11/25/2022 | 11/30/2026 | Ordinary Shares | 70,422 | $0.2 | D | |
| Explanation of Responses: |
| 1. Granted on December 12, 2025. 2,271,333 options will vest on July 1, 2026, 2,271,333 options will vest on July 1, 2027 and 2,271,334 options will vest on July 1, 2028 provided Mr. Turner is still a Director on such dates. |
| 2. Granted on December 16, 2024. 2,666,667 options will vest on September 30, 2026 and 2,666,666 options will vest on September 30, 2027 provided Mr. Turner is still a Director on such dates. |
| 3. Granted on December 16, 2024. 1,346,801 options will vest on July 1, 2026 and 1,346,802 options will vest on July 1, 2027 subject to Mr. Turner achieving certain milestones. |
| 4. Granted on December 1, 2023. 483,768 options will vest on July 1, 2026 subject to Mr. Turner achieving certain milestones. |
| Remarks: |
| 1. All exercise prices are in Australian dollars. |
| /s/ Ian Lawrence Turner | 04/01/2026 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||
| * Form 3: SEC 1473 (03-26) | ||